View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, July 22 (HealthDay News) -- The U.S. Food and Drug Administration has informed GlaxoSmithKline (GSK), the manufacturer of rosiglitazone (Avandia), that the Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) trial has been placed on partial clinical hold, one week after an FDA advisory panel recommended that the diabetes drug remain on the market with tightened controls or restricted sales due to cardiovascular safety concerns.
Under the partial clinical hold, enrollment of new patients into the trial will be suspended until further notification from the FDA. However, patients already enrolled will be allowed to continue with the trial. Although the drug seems to increase cardiovascular risks, the FDA advisory panel voted during the meeting, held on July 13 and 14, to keep the drug on the market because the evidence was not conclusive.
The FDA has directed GSK to update investigators, institutional review boards, and ethics committees involved in the TIDE trial about the new safety data presented at the meeting, which may be used to update existing consent information for participants currently enrolled in the trial. In a press release, GSK confirmed that they will halt new patient enrollment into the TIDE trial and will work with the TIDE steering committee to distribute a summary of the updated safety information and recent meeting deliberations.
According to a statement from the agency, "the FDA is evaluating available information on Avandia's safety and the discussions of the recent advisory committee meeting. The FDA will update the public on the outcome of its review and its implications for Avandia and the TIDE trial when the review is complete."
Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com
BD Safety Beyond Needlestick Prevention Learning Center
Sponsored by BD Medical
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top